The independent financial analyst theScreener just requalified the general evaluation of INTREXON CORP. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date September 3, 2019, the closing price was US...
Summary Marketline's Aevi Genomic Medicine, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Aevi Genomic Medicine, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdo...
Summary Intrexon Corp (Intrexon), formerly Genomatix Corp is a provider of therapeutic solutions. The company operates through its divisions such as human therapeutics, protein production, industrial products, agricultural biotech, and animal sciences. Its human therapeutics division develops therapeutic product candidates for lysosomal storage diseases, hematological disorders, metabolic diseases, infectious diseases, and autoimmune disorders. Intrexon’s UltraVector platform produces and opt...
NEW YORK--(BUSINESS WIRE)-- Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Intrexon Corporation (“Intrexon” or the “Company”) (NYSE:XON) focusing on potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). Intrexon, headquartered in Germantown, Maryland, is a biotechnology company focused on synthetic biology and gene-based technologies. Newman Ferrara’s investigation focuses on decisions made by the Board, including material decision...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.